QUÉBEC CITY, June 13, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:
AEZS) (TSX: AEZ) (the "Company") today announced that Brian H. Kushner,
MD, of the Memorial Sloan-Kettering Cancer Center in New York, will be
making a poster presentation on Phase 1 results for perifosine in
neuroblastoma, at the Advances in Neuroblastoma Research Conference
which will be held June 18-21, 2012, at the Fairmount Royal York Hotel
in Toronto.
|
Poster #POC27:
|
"Targeting PI3K/Akt Pathway: Perifosine Monotherapy for Resistant
Neuroblastoma in a Phase 1/1B Study", B. Kushner, N-K.V. Cheung,
S. Modak, O. Becher, E.M. Basu, S.S. Roberts, K. Kramer, I.J. Dunkel.
|
| |
|
|
Date and time:
|
Wed., June 20, 2012, 12:30 pm - 2:30 pm + 5:30 pm - 6:30 pm (Eastern)
|
| |
|
|
Venue:
|
Royal Canadian Ballroom, Fairmount Royal York Hotel, Toronto
|
| |
|
About Perifosine
Perifosine is a novel, oral PI3K/Akt inhibitor compound. It is currently
in a Phase 3 trial in multiple myeloma for which it has been granted
orphan drug and Fast Track designations by the Food and Drug
Administration (FDA), as well as positive Scientific Advice and orphan
medicinal product designation from the European Medicines Agency. It
has also been granted orphan drug designation by the FDA for
neuroblastoma. Furthermore, perifosine is in earlier-stage development
for other cancer indications.
About Aeterna Zentaris
Aeterna Zentaris is an oncology and endocrinology drug development
company currently investigating treatments for various unmet medical
needs. The Company's pipeline encompasses compounds at all stages of
development, from drug discovery through to marketed products. For more
information please visit www.aezsinc.com.
SOURCE AETERNA ZENTARIS INC.
